Suicide Attempt with High Dose Long Acting Methylphenidate Ingestion: A Case Presentation

Q Medicine Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology Pub Date : 2016-11-08 DOI:10.5455/BCP.20151223093022

Handan Özek Erkuran, B. Çakaloz, Özlem Önen, A. Kutlu

{"title":"Suicide Attempt with High Dose Long Acting Methylphenidate Ingestion: A Case Presentation","authors":"Handan Özek Erkuran, B. Çakaloz, Özlem Önen, A. Kutlu","doi":"10.5455/BCP.20151223093022","DOIUrl":null,"url":null,"abstract":"ABSTRACTAttention Deficit and Hyperactivity Disorder (ADHD) is among the most commonly encountered neurodevelopmental disorders in childhood with its reported worldwide prevalance as 5%. Among the recommended treatment regimens as stimulants, the most frequently advised ones are methylphenidate (MPH) preparates. Among long acting MPH preparates, the form that contains an osmotic release oral system (MPH-OROS) is frequently used in clinical practice. Studies about risks, causes and outcomes regarding high dose MPH intake and effects of high dose MPH preparates in humans are limited. This article presents the clinical picture of a 12 year old boy who attempted suicide by ingesting 15 tablets of 36- mg MPH OROS. Exposure to an overdose of MPH-OROS exhibited acute sympathomimetic toxicity but no life-threatening symptoms in this patient. This case report might suggest that higher doses of MPH-OROS could be tolerated well under fine clinical observation and management; although more larger scale studies in thi...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5455/BCP.20151223093022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 4

Abstract

ABSTRACTAttention Deficit and Hyperactivity Disorder (ADHD) is among the most commonly encountered neurodevelopmental disorders in childhood with its reported worldwide prevalance as 5%. Among the recommended treatment regimens as stimulants, the most frequently advised ones are methylphenidate (MPH) preparates. Among long acting MPH preparates, the form that contains an osmotic release oral system (MPH-OROS) is frequently used in clinical practice. Studies about risks, causes and outcomes regarding high dose MPH intake and effects of high dose MPH preparates in humans are limited. This article presents the clinical picture of a 12 year old boy who attempted suicide by ingesting 15 tablets of 36- mg MPH OROS. Exposure to an overdose of MPH-OROS exhibited acute sympathomimetic toxicity but no life-threatening symptoms in this patient. This case report might suggest that higher doses of MPH-OROS could be tolerated well under fine clinical observation and management; although more larger scale studies in thi...

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

高剂量长效哌甲酯摄入自杀企图:一例报告

摘要注意缺陷多动障碍(ADHD)是儿童时期最常见的神经发育障碍之一，据报道其全球患病率为5%。在作为兴奋剂的推荐治疗方案中，最常被建议的是哌甲酯制剂。在长效MPH制剂中，含有渗透释放口服系统(MPH- oros)的形式常用于临床实践。关于高剂量MPH摄入的风险、原因和结果以及高剂量MPH制剂对人类的影响的研究是有限的。这篇文章提出了临床图片的12岁男孩谁企图自杀服用15片36毫克的MPH OROS。过量暴露于MPH-OROS表现出急性拟交感神经毒性，但没有危及生命的症状。本病例报告提示，在良好的临床观察和管理下，高剂量的MPH-OROS是可以耐受的;尽管这方面更大规模的研究…

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊